Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?

Notably, RHHBY stock has underperformed the broader market in each of the last 3 years. Returns for the stock were 18% in 2021, -24% in 2022, and -7% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that RHHBY underperformed the S&P in 2021, 2022, and 2023. Roche's revenue has declined 7.2% from $72.4 billion in 2021 to $67.2 billion in 2023. This can primarily be attributed to lower demand for its Covid-19 testing. Excluding the Covid-19 prod ...